Title
Microduplications of 16p11.2 are associated with schizophrenia

Permalink
https://escholarship.org/uc/item/7s81v6x$s

Journal
Nature Genetics, 41(11)

ISSN
1061-4036

Authors
McCarthy, SE
Makarov, V
Kirov, G
et al.

Publication Date
2009-11-01

DOI
10.1038/ng.474

Peer reviewed
Microduplications of 16p11.2 are Associated with Schizophrenia

A full list of authors and affiliations appears at the end of the article.

Abstract

Recurrent microdeletions and microduplications of a 600 kb genomic region of chromosome 16p11.2 have been implicated in childhood-onset developmental disorders\(^1\)\(^-\)\(^3\). Here we report the strong association of 16p11.2 microduplications with schizophrenia in two large cohorts. In the primary sample, the microduplication was detected in 12/1906 (0.63%) cases and 1/3971 (0.03%) controls (\(P=1.2\times10^{-5}, OR=25.8\)). In the replication sample, the microduplication was detected in 9/2645 (0.34%) cases and 1/2420 (0.04%) controls (\(P=0.022, OR=8.3\)). For the series combined, microduplication of 16p11.2 was associated with 14.5-fold increased risk of schizophrenia (95% C.I. [3.3, 62]). A meta-analysis of multiple psychiatric disorders showed a significant association of the microduplication with schizophrenia, bipolar disorder and autism. The reciprocal microdeletion was associated only with autism and developmental disorders. Analysis of patient clinical data showed that head circumference was significantly larger in patients with the microdeletion compared with patients with the microduplication (\(P = 0.0007\)). Our results suggest that the microduplication of 16p11.2 confers substantial risk for schizophrenia and other psychiatric disorders, whereas the reciprocal microdeletion is associated with contrasting clinical features.

Rare structural mutations play an important role in schizophrenia. Recent studies have shown that the genome-wide burden of rare copy number variants (CNVs) is significantly greater in patients than in healthy controls\(^4\)\(^-\)\(^6\). In addition, multiple structural variants have been implicated in schizophrenia. Seminal examples include the recurrent microdeletion of 22q11.2\(^7\), and a balanced translocation disrupting the gene DISC1\(^8\). More recently,
recurrent microdeletions at 1q21.1, 15q13.3, 5, 9 and 15q11.2, 6, 9 and copy number mutations at other genomic loci,10, 12 have been associated with schizophrenia in large cohorts.

We previously reported two cases of childhood-onset schizophrenia (COS) with a 600 kb microduplication of 16p11.2. This region is a well documented hot spot for recurrent rearrangements in association with autism spectrum disorders and mental retardation.1, 3, 13, 14 Genomic hotspots such as this are important candidate loci in genetic studies of schizophrenia.

We tested the hypothesis that microduplications of 16p11.2 are associated with schizophrenia by analysis of microarray intensity data in a sample of 1906 cases and 3971 controls. Patients and controls were drawn from several different sources, as described in the supplemental note and supplementary table 1. Samples were analyzed with one of four microarray platforms (NimbleGen HD2, Affymetrix 6.0, Affymetrix 500K and ROMA 85K). Only the 16p11.2 region was examined. Thirteen microduplications and four microdeletions were detected in our primary sample using standard segmentation algorithms (Figure 1A, Supplementary Figure 1A). Microduplications were detected in 12/1906 cases (0.63%) and 1/3971 controls (0.03%), a statistically significant association (Table 1, \( P = 1.2 \times 10^{-5}, \text{OR} = 25.8 \ [3.3, 199] \)).

In a subset of individuals evaluated at Cold Spring Harbor Laboratory, consisting of 1352 cases and 1179 controls, CNV calls were verified by MeZOD, an independent CNV genotyping algorithm that identifies outliers in the sample based on the median probe Z-score of the target region. These results are illustrated in Figure 1 as cluster plots. All microduplications and microdeletions detected in the combined sample were experimentally validated using an independent microarray platform (Supplementary Table 2).

In order to replicate this association, we evaluated the 16p11.2 region using microarray data (Affymetrix 6.0 platform) from an independent sample of 2645 schizophrenia cases and 2420 controls. These data were collected as part of a case-control study of schizophrenia supported by the Genetic Association Information Network (GAIN, phs000021.v2.p1). We detected ten duplications and one deletion using standard HMM calling algorithms (Figure 1A). The same events were also detected using MeZOD (Figure 1E). All 16p11.2 rearrangements were validated by an independent microarray platform (Supplementary Table 2). The microduplication was detected in 9/2645 cases and 1/2420 controls, a significant association (\( P = 0.022, \text{OR}=8.3 \ [1.3, 50.5] \)).

The odds ratios in our primary and replication datasets were not significantly different (Breslow-Day-Tarone test \( P = 0.46 \)). Thus, our initial result was replicated in an independent sample. For the combined sample, the association of schizophrenia with microduplication at 16p11.2 was highly significant (\( P=4.3 \times 10^{-7}, \text{OR}=14.5 \ [3.3, 62] \)). Sex of the subject did not have a significant effect on the association (Supplementary Note).

Our present findings, and those from previous studies,1-3, 13, 14 suggest that mutations at 16p11.2 confer high risk for schizophrenia and for other neuropsychiatric disorders. Clinical variability associated with the 16p11.2 microduplication is evident from the heterogeneity of psychiatric diagnoses among microduplication carriers in five families in our series.
(Supplementary Figure 2). In these families, ten relatives carried the microduplication found in the proband. The diagnoses of these relatives were: schizophrenia (N=3), bipolar disorder (N=1), depression (N=2), psychosis signs not otherwise specified (N=1), and no mental illness (N=3). We were able to determine the parent of origin in four families, and in all cases the microduplications were inherited from a non-schizophrenic parent. The observations in these few families suggest that penetrance of the duplication is incomplete, though substantial (perhaps 30-50%), and that expression is highly variable.

In order to more precisely define the spectrum of psychiatric phenotypes associated with rearrangements of 16p11.2, we performed a meta-analysis of data on schizophrenia, bipolar disorder, and childhood developmental disorders (combining autism and global developmental delays). We integrated data from this study with four publicly available datasets to generate a combined sample of 8590 individuals with schizophrenia, 2172 with developmental delay or autism, 4822 with bipolar disorder, and 30,492 controls (Supplementary Note, Supplementary Table 3). In this combined sample, the microduplication of 16p11.2 was strongly associated with schizophrenia (Table 2, OR = 8.4 [2.8, 25.4], P = 4.8×10⁻⁷) and autism (OR = 20.7 [6.9, 61.7], P = 1.9×10⁻⁷). The association with bipolar disorder was also significant (OR = 4.3 [1.3; 14.5], P = 0.017). The reciprocal microdeletion of 16p11.2 was strongly associated with developmental delay or autism (OR = 38.7 [13.4, 111.8], P = 2.3×10⁻¹³), as reported previously. However, the deletion was not associated with schizophrenia or bipolar disorder (Supplementary Note). These results suggest that the microduplication is associated with multiple psychiatric phenotypes, whereas the reciprocal microdeletion is more specifically associated with developmental delay and autism.

We explored the association of 16p11.2 microduplications and microdeletions with two clinical measures, head circumference and height. Available data were compiled from 32 patients with 16p11.2 mutations who had a diagnosis of schizophrenia, autism spectrum disorder or developmental delay (Supplementary Note, Supplementary Tables 4 and references). Z-scores for head circumference and height were calculated using standard growth charts from the Centers for Disease Control. Head circumference was greater among 23 patients with microdeletions relative to 9 patients with microduplications (Supplementary Table 5). The mean orbital frontal circumference (OFC) values of patients with microdeletions and microduplications were 1.25 and -0.28, respectively (two-tailed Wilcoxon Rank Sum Test P = 0.0007). In addition, mean head circumference of the microdeletion group was significantly greater than the population mean (P = 0.0001), whereas the mean head circumference of the microduplication group was not statistically significant (P = 0.29). The association between the 16p11.2 microdeletion and larger head circumference was observed in multiple diagnostic categories and was not specifically attributable to patients with autism (Supplemental Table 5). The microduplication and microdeletion groups did not differ significantly in height.

Microduplication of 16p11.2 is associated with increased risk of schizophrenia between 8 and 24-fold. This region joins a growing list of genomic hotspots that confer high risk for the disorder. The odds ratios in our series for the 16p11.2 microduplication and schizophrenia are comparable to odds ratios for deletions at other schizophrenia-associated
genes and regions. Deletions of 1q21.1, 15q13.3, and NRXN1 have reported odds ratios ranging from 7 to 18, with differences in expression between normal and affected individuals. Previous genome-wide studies of copy number variation did not find a significant association with the microduplication of 16p11.2 and schizophrenia. This event is rare, and its appearance in a cohort may be influenced by several factors, including resolution of the detection platform, methods of analysis, and chance. In the International Schizophrenia Consortium (ISC) study, microduplications spanning >50% of the 16p11.2 region were detected in 5/3391 cases and 1/3181 controls. These results are consistent with our findings, but the association did not meet the criteria for genome-wide significance in that study. In the SGENE consortium study of schizophrenia, the 16p11.2 microduplication was not selected as a candidate because the event was not observed in the initial phase of that study as a de novo mutation, which was the key criterion for inclusion in the association analyses. Microduplication at 16p11.2 is associated with multiple neuropsychiatric phenotypes. Phenotypic heterogeneity has been observed for virtually all structural variants associated with schizophrenia. For example, in a large Scottish pedigree harboring a translocation disrupting DISC1, translocation carriers had diagnoses of schizophrenia, bipolar disorder, major depressive disorder, or no mental illness. Similarly, microdeletions of 1q21.1, 15q13.3, 22q11.2, and neurexin-1 are associated with adult psychiatric disorders and with autism and other pediatric neurodevelopmental disorders.

The association between the 16p11.2 microdeletion and increased head circumference is interesting given that the microdeletion appears specific to autism and developmental delay. Several studies have found increased head circumference in patients with autism, leading to the suggestion that early brain overgrowth may be a key neurobiological mechanism in the disorder. A recent study has shown that microdeletions and microduplications of 1q21.1 are associated with microcephaly and macrocephaly respectively. Taken together, these studies suggest that some mutations underlying neurodevelopmental disorders may also lead to changes in brain volume.

The 16p11.2 microduplication spans a region of approximately 600kb containing 28 genes (Supplementary Figure 1B), including multiple genes with potential roles in neurodevelopment. At least 17 of the 28 genes are expressed in the mammalian brain (Supplementary Table 6). Behavioral features have been reported in mouse knockout models of Mapk3-/-Doc2a-/- and Sec62-/-. Further studies are needed in order to identify the specific gene or genes in this region for which dosage effects contribute to increased risk for psychiatric and neurodevelopmental disorders.

Our findings further strengthen the evidence demonstrating a role for rare mutations in schizophrenia. Collectively, these studies demonstrate that schizophrenia is characterized by marked genetic heterogeneity. The 16p11.2 locus by itself accounts for only a small fraction of the illness. At the same time, duplication of this region confers substantial risk to the individuals who carry it. The fact that a single mutation is rare does not negate its potential relevance to the broader patient population. The collective effect of rare mutations at many different loci may account for a substantial proportion of affected individuals.
Furthermore, the microduplication of 16p11.2 and rare mutations at other loci will likely impact overlapping neurobiological pathways. Characterizing these critical brain processes will contribute substantially to our understanding of the origins of schizophrenia and provide important targets for treatment development.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Shane McCarthy1, Vladimir Makarov1, George Kirov2, Anjene Addington3, Jon McClellan4, Seungtai Yoon1, Dianna Perkins5, Diane E. Dickel6, Mary Kusenda1,7, Olga Krastoshevsky8, Verena Krause8, Ravinesh A. Kumar9, Detelina Grozeva2, Dheeraj Malhotra1, Tom Walsh5, Elaine H. Zackai10, Paige Kaplan11, Jaya Ganesh11, Ian D. Krantz11, Nancy B. Spinner10, Patricia Roccanova1, Abhishek Bhandari1, Kevin Pavon1, B. Lakshmi1,12, Anthony Leotta1, Jude Kendall1, Yoon-ha Lee1, Vladimir Vacic1, Sydney Gary1, Lilia Iakoucheva13, Timothy J. Crow14, Susan L. Christian9, Jeffrey Lieberman15, Scott Stroup5, Terho Lehtimäki16, Kaija Puura17, Chad Haldeman-Englert10, Justin Pearl18, Meredith Goodell19, Virginia L. Willour19, Pamela DeRosse20, Jo Steele18, Layla Kassem18, Jessica Wolff18, Nisha Chitkara20, Francis J. McMahon18, Anil K. Malhotra20, James B. Potash19, Thomas G. Schulze18,21, Markus M. Nöthen22,23, Sven Cichon22,23, Marcella Rietschel21,24, Ellen Leibenluft25, Vlad Kustanovich26, Clara M. Lajonchere26, James S. Sutcliffe27, David Skuse28, Michael Gill29, Louise Gallagher29, Nancy R. Mendell30, Wellcome Trust Case Control Consortium31, Nick Craddock2, Michael J. Owen2, Michael C. O’Donovan2, Tamim H. Shaikh10, Ezra Susser15, Lynn E. DeLisi32,33, Patrick F. Sullivan34, Curtis K. Deutsch32,35, Judith Rapoport3, Deborah L. Levy8,32, Mary-Claire King6, and Jonathan Sebat1

Affiliations

1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA 2Department of Psychological Medicine, School of Medicine, Cardiff University, Cardiff, UK 3Child Psychiatry Branch, National Institute for Mental Health, National Institutes of Health, Bethesda, Maryland, USA 4Department of Psychiatry, University of Washington, Seattle, Washington, USA 5Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina USA 6Department of Genome Sciences, University of Washington, Seattle, Washington, USA 7Graduate Program in Genetics State University of New York, Stony Brook, New York, USA 8Psychology Research Laboratory, McLean Hospital, Belmont, Massachusetts, USA 9Department of Human Genetics, University of Chicago, Chicago, Illinois, USA 10Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA 11Section of Biochemical Genetics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA 12Ontario Institute for Cancer Research, Toronto, Ontario, Canada 13Laboratory of Statistical Genetics, The Rockefeller University, New York, USA 14The Prince of Wales International Center for SANE Research.
Warneford Hospital, Oxford, UK 15College of Physicians and Surgeons of Columbia University, Columbia University, New York, USA 16Department of Clinical Chemistry, University of Tampere, Tampere, Finland 17Department of Child Psychiatry, Tampere University and University Hospital, Tampere, Finland 18Genetic Basis of Mood and Anxiety Disorders Unit, National Institute for Mental Health, National Institutes of Health, Bethesda, Maryland, USA 19Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA 20Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, New York, USA 21Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, University of Heidelberg, Germany 22Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany 23Institute of Human Genetics, University of Bonn, Bonn, Germany 24Department of Psychiatry and Psychotherapy, University of Bonn, Germany 25Mood and Anxiety Disorders Program, National Institute for Mental Health, National Institutes of Health, Bethesda, Maryland, USA 26Autism Genetic Resource Exchange, Autism Speaks, Los Angeles, California, USA 27Center for Molecular Neuroscience, Vanderbilt University, Nashville, Tennessee, USA 28Behavioral Sciences Unit, Institute of Child Health University College London, London, UK 29Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland 30Department of Applied Mathematics and Statistics, State University of New York, Stony Brook, New York, USA 31Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA 32Brockton VA Boston Health Care Services, Brockton, Massachusetts, USA 33Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA 34Eunice Kennedy Shriver Center, University of Massachusetts Medical School, Waltham, Massachusetts, USA

Acknowledgments

Funding for this study was provided by grants from Ted and Vada Stanley, the Simons Foundation, grants from NARSAD to FJM, TGS, DLL, MCK and TW, and grants from the Essel Foundation and the Sidney R. Baer, Jr. Foundation to DLL and from the Margaret Price Investigatorship to JBP and VLW. This work was supported by grants from the National Institutes of Health Intramural Research Program, National Institutes of Health, including NIMH grant MH076431 to JS, which reflects co-funding from Autism Speaks, and the Southwestern Autism Research and Resource Center, as well as NIH grants to JS (HF004222), MCK, TW, and JMC (MH083989), DLL and NRM (MH071523; MH31340), JMC (RR000037), PFS (MH074027 and MH077139), JSS (MH061009), LED (MH44245), THS (GM081519) and CKD (MH081810; DE016442; HD04147). Funding for GK, NC, MJO and MCO was provided by the Medical Research Council, UK, and the Wellcome Trust. The CATIE project was funded by NIMH contract N01 MH90001. Genotyping of the Molecular Genetics of Schizophrenia study (PI Pablo Gejman) was funded by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health. Genotype data were obtained from dbGaP (http://www.ncbi.nlm.nih.gov/dbgap, accession number phs000021.v2.p1). This study makes use of data generated by the Wellcome Trust Case Control Consortium (full list of contributors is presented in the supplementary online material). Funding for that project was provided by the Wellcome Trust under award 076113. Microarray data and clinical information were provided by the Genetic Association Information Network (GAIN). Thanks to the New York Cancer Project, Peter Gregersen and Annette Lee for providing population control samples. Also, we wish to thank Drs. Pablo Gejman and Douglas Levinson for helpful discussions. Special thanks to Dr. James Watson for helpful discussions and support.

References


Nat Genet. Author manuscript; available in PMC 2010 October 07.
Figure 1. Microduplications and microdeletions at 16p11.2 in persons with schizophrenia and controls
(A) 16p11.2 rearrangements were detected in a primary sample of 1906 cases and 3971 controls (Panels A, B, C, D) and a replication sample of 2645 cases and 2420 controls (Panel A, E). The single microduplication and three microdeletions detected in the primary control set are presented based on the Affymetrix 500K coordinates (hg18). All other CNVs were validated in the NimbleGen HD2 platform and are illustrated based on the validation coordinates (Panels B, C, D, E) The median z-score for the 535kb 16p11.2 target region is plotted on the X-axis and the median z-score of flanking invariant probes is plotted on the Y-axis. Data are presented separately for the ROMA (B), Affymetrix500K (C), NimbleGen HD2 (D), and (Affymetrix 6.0 (E) platforms. CNVs were called using thresholds of >2 SD for ROMA and >1 SD for all other platforms (●). MeZOD and the HMM algorithms detected the same deletions and duplications at 16p11.2.
Table 1

Duplications and deletions at 16p11.2 among persons with schizophrenia and controls

<table>
<thead>
<tr>
<th>Series</th>
<th>Diagnosis</th>
<th>Subjects</th>
<th>Deletions</th>
<th>Duplications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N</td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Primary</td>
<td>Schizophrenia</td>
<td>1906</td>
<td>1 (0.05)</td>
<td>12 (0.63)</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>3971</td>
<td>3 (0.08)</td>
<td>1 (0.03)</td>
</tr>
<tr>
<td>Replication</td>
<td>Schizophrenia</td>
<td>2645</td>
<td>0 (0.00)</td>
<td>9 (0.34)</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>2420</td>
<td>1 (0.04)</td>
<td>1 (0.04)</td>
</tr>
<tr>
<td>Combined</td>
<td>Schizophrenia</td>
<td>5877</td>
<td>1 (0.02)</td>
<td>21 (0.36)</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>6391</td>
<td>4 (0.06)</td>
<td>2 (0.03)</td>
</tr>
</tbody>
</table>

In the primary sample, which consisted of patients and controls genotyped using one of 3 microarray platforms, association was calculated using the Cochran-Mantel-Haenszel exact test using array type as a stratifying variable. Combined odds ratio estimates and 95% confidence intervals were calculated using a logistic regression with disease group and array-type as factors. In the replication sample, which consisted of patients and controls assessed on a single microarray platform, association was calculated using a Fisher’s exact test. Deletions did not show a significant association with schizophrenia or in controls.
Table 2

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Subjects</th>
<th>Deletions</th>
<th>Duplications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N %</td>
<td>OR[95% CI]</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>8590</td>
<td>3 0.03</td>
<td>NC*</td>
</tr>
<tr>
<td>Controls</td>
<td>28406</td>
<td>9 0.03</td>
<td></td>
</tr>
<tr>
<td>Autism or Developmental Delay</td>
<td>2172</td>
<td>17 0.78</td>
<td>38.7 [13.4,111.8]</td>
</tr>
<tr>
<td>Controls</td>
<td>24891</td>
<td>5 0.02</td>
<td></td>
</tr>
<tr>
<td>Bipolar Disorder</td>
<td>4822</td>
<td>4 0.08</td>
<td>NC*</td>
</tr>
<tr>
<td>Controls</td>
<td>25225</td>
<td>6 0.02</td>
<td></td>
</tr>
</tbody>
</table>

*Not calculated (NC) because significant heterogeneity among studies was detected by the Breslow-Day Tarone test. The partial odds ratios [95%CI] for the deletion in schizophrenia were 0.69 [0.1, 4.9], 0.3 [0.05, 2.2], 14.6 [1.9, 111.2], and 0.3 [0.03, 3.7] and partial odds ratios for the deletion in bipolar disorder were 0.3[0.03,3.3], 0.55[0.05,6.7], 25[5.4,117] in this study, the GAIN study and the Weiss et al. studies, respectively.

Data from four studies reporting microduplications and microdeletions of 16p11.2 in schizophrenia, autism and/or bipolar disorder were combined with data from the Primary Sample to assess the relative strength of the association of each variant with each disorder. Associations were calculated using the Cochran-Mantel-Haenszel exact test, using source as a stratifying variable. Combined odds ratio estimates and confidence intervals were calculated from logistic regression with disease group and source (study) as factors.